| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 484.72 | 0.1% | 4.0% |
| Total Income | 493.18 | 1.1% | 4.8% |
| Expenditure | 469.89 | 3.8% | 5.7% |
| PBT | 23.29 | 34.3% | 9.4% |
| Net Profit | 15.74 | 42.8% | 22.5% |
| OPM | 5.04% | 4.53pp | 4.03pp |
| NPM | 3.19% | 2.45pp | 1.13pp |
| EPS | 0.28 | 44.0% | 20.0% |
Morepen Labs Q4 Net Profit Rises 69% to ₹20 Cr
27 May 2026 · 27 May, 8:27 am
Summary
Morepen Laboratories Limited delivered a robust Q4 FY26 performance, with net profit surging 69% year-on-year to ₹20 crore and gross revenue increasing 22% to ₹472 crore, bolstered by export demand and Medical Devices segment expansion. For the full fiscal year, standalone gross revenue surpassed ₹1,700 crore, reflecting an 8% rise, with the Medical Devices business growing 21% to ₹598 crore. The company's EBITDA for Q4 FY26 stood at ₹32 crore, slightly lower than ₹33 crore in Q4 FY25, reflecting strategic growth investments. Management highlighted the commencement of commercial production for a significant CDMO mandate and ongoing capacity expansion from approximately 500 KL to 800 KL, signaling a strategic shift towards long-duration manufacturing partnerships and improved operating leverage for long-term growth visibility.
Key Highlights
- 1
Morepen Laboratories Limited reported a strong Q4 FY26 net profit increase of 69% year-on-year to ₹20 crore.
- 2
Gross revenue for Q4 FY26 grew by 22% year-on-year to ₹472 crore, driven by export momentum and Medical Devices business expansion.
- 3
For the full financial year FY26, standalone gross revenue crossed ₹1,700 crore, marking an 8% increase.
- 4
The Board has proposed a 10% dividend to shareholders for FY26.
- 5
The company successfully completed its 4th consecutive USFDA inspection with NIL 483 observations.
- 6
Commercial production commenced under a long-duration manufacturing partnership program, backed by an ₹825 crore / USD 91 million global CDMO mandate received in February 2026.
- 7
Capacity expansion is underway, increasing from approximately 500 KL towards 800 KL, with a longer-term roadmap toward 1000 KL.
Management Comments
Mr. Sushil Suri
Over the years, Morepen has built strong manufacturing capabilities, regulatory credibility and global customer relationships. We are now entering the next phase of growth focused on long-duration manufacturing partnerships, scale expansion and improved operating leverage.
Mr. Sushil Suri
The Company’s business is progressively evolving from a traditional API model toward a manufacturing-led platform driven by long-duration customer programs, recurring revenues, process scale-up and regulated-market partnerships.
Mr. Sanjay Suri
We are expanding manufacturing capacity from ~500 KL toward ~800 KL, with a longer-term roadmap toward ~1000 KL. Increasing scale, improved product mix and long-duration supply programs are expected to support stronger margins and earnings visibility over the medium term.
Mr. Sanjay Suri
The Company has also completed a pivotal bioequivalence study for Resmetirom 100 mg, an oral thyroid hormone receptor-beta agonist used in the treatment of moderate to advanced liver fibrosis associated with MASH. The study covers major regulated markets outside the US and represents an important step in strengthening Morepen’s globally relevant specialty pipeline.
Informational and educational content only. Not investment advice.